HOME >> MEDICINE >> NEWS
Investigational drug may protect cancer and AIDS patients from side effects of pain relief therapy

A drug developed to relieve one of the major side effects of pain therapy for cancer patients may offer an added benefit for AIDS patients, researchers from the University of Chicago and the Children's Hospital of Philadelphia reported Saturday, October 11, at the 2003 Annual Meeting of the American Society of Anesthesiologists in San Francisco.

Methylnaltrexone (MNTX) was invented to reverse the constipation caused by powerful opioid-based pain relievers such as morphine, OxyContin or Percocet taken by patients with cancer or AIDS. Opiates also appear to increase the ability of HIV to infect certain immune system cells.

This laboratory study found that MNTX blocked increases in HIV entry and replication that occur when immune cells are exposed to therapeutic doses of morphine. In this in-vitro study, very small amounts of methylnaltrexone blocked this process.

"If our studies are borne out in future clinical trials, methylnaltrexone may improve the care of patients who take opioids for pain caused by AIDS," said Jonathan Moss, M.D., Ph.D., professor of anesthesia and critical care at the University of Chicago and director of the study.

Many AIDS patients and more than 500,000 patients with advanced cancer depend on drugs like morphine for pain relief. One side effect of these pain relievers is severe constipation, which can be so distressing that many patients discontinue their pain medication.

Methylnaltrexone was invented to solve this problem by the late Leon Goldberg, a University of Chicago pharmacologist. To help a dying friend with morphine-induced constipation, Goldberg took naltrexone, an established drug that blocks the effects of morphine, and altered it slightly so that it could no longer cross the protective barrier that surrounds the brain.

Consequently, it did not interfere with morphine's effect on pain, which is centered in the brain, but it did block morphine's effects on gut motility, which a
'"/>

Contact: John Easton
jeaston@uchospitals.edu
773-702-6241
University of Chicago Medical Center
14-Oct-2003


Page: 1 2

Related medicine news :

1. Investigational transplant drug effectively preserves kidneys while avoiding toxic side effects
2. Investigational drug may provide new option for preventing transplant organ rejection
3. Investigational drug brings new hope to kidney cancer patients
4. Investigational mesh jackets studied as an experimental therapy for heart failure
5. Investigational oral contraceptive reduces premenstrual and menstrual symptoms
6. Investigational drug study may determine if lung cancer is preventable in cigarette smokers
7. New study in Nature demonstrates protection against cell death during heart attack
8. Simple intervention encourages sun protection behaviors
9. Red wine protects the heart
10. Sunflower seed oil can protect low birth weight babies from infection
11. Physical activity linked to protection from Parkinsons disease

Post Your Comments:
(Date:4/25/2015)... Providenciales, Turks and Caicos Islands, BWI (PRWEB) April 25, ... Providenciales International Airport (PLS) has celebrated three months of ... since reopening on January 5, 2015. , As ... phases, the interior of Providenciales airport was completely redesigned ... area has quickened up the process of getting out ...
(Date:4/25/2015)... April 25, 2015 On Friday, April ... RFID Journal’s annual Best Implementation Award. This award ... the best use of RFID technology to improve its ... the company that best demonstrates how RFID is delivering ... at RFID Journal Live! 2015 in San Diego, the ...
(Date:4/24/2015)... AK (PRWEB) April 24, 2015 As ... (#MOTMC2015) and the unique sacrifices of these young men ... for Service members, Veterans and their Families” presents a ... training is designed to gain a better understanding of ... health and wellness. For those – civilian and military ...
(Date:4/24/2015)... The 1975 have had an intense ... globe to theaters, festivals and TV performances. Now that they’ve ... their label, Dirty Hit Records, to provide clean drinking water ... launched Cadence & Cause website, this four-piece has ... and a signed photo card. Entries from this sweepstakes ...
(Date:4/24/2015)... Anchor Health Administrators (Anchor), specialists in Long-Term ... their exclusive agreement with LTC Solutions for All LLC ... partner. , Anchor has more than 18 years of ... associations, and is currently the designated advocate for the ... Insurance member benefit. , “I am very pleased to ...
Breaking Medicine News(10 mins):Health News:The Tuscany on Grace Bay Celebrates Providenciales Airport Expansion With Summer Specials to Travelers! 2Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2
(Date:4/24/2015)... , April 24, 2015  Lannett Company, Inc. (NYSE: ... and increased its five-year revolving credit facility to $120 ... accordion feature that will allow the company to increase ... $30.0 million, subject to securing additional commitments from existing ... the credit facility remains December 18, 2018.   ...
(Date:4/24/2015)... 2015 Hospira, Inc. (NYSE: ... biosimilar therapies, spoke about the importance of extrapolation in ... Association (EGA) annual European Biosimilars Group conference in ... announced the publication of a pivotal white paper titled, ... promise of biosimilars." Speaking at the ...
(Date:4/24/2015)... April 24, 2015  Blueprint Medicines today announced ... and potent inhibitor of fibroblast growth factor receptor ... of hepatocellular carcinoma (HCC) that are dependent on ... induced complete tumor regression in a subset of ... at the highest dose levels. These data will ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3
Cached News: